UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of **January 2022**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: January 10, 2022

By: /s/ Dorit Kreiner
Dorit Kreiner
Chief Financial Officer

Exhibit 99.1


BIOMICA
Microbiome-Empowered Therapeutics
Dr. Elran Haber, CEO • January 2022
© 2022 Biomica LTD. All rights reserved.

Forward-looking statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries, including Biomica Ltd. ("Biomica") (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Biomica claims the protection of the safe harbor for forward-looking statements contained in the PSLRA and other securities laws.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Biomica and Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Biomica's and Evogene's control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information it files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirely by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Biomica and Evogene disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.



We are Biomica

An emerging biopharmaceutical company with cutting edge computational capabilities to develop the most optimized microbiome-based therapeutics.

Rooted in excellence

Subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), a pioneer in the field of applied computational predictive biology, creating next-generation life sciences products.

Breakthrough platform

Drug candidates identified and designed with PRISM– a proprietary computational platform combining AI capabilities with big data.

Spearheading the future

Optimized discovery, design & development, resulting in best-in-class pharmaceuticals.

Precise & efficient – from concept to clinical trials in only 3 years.

Our Mission

To discover & develop novel therapies for microbiome-related human disorders.

We utilize computational predictive biology to provide new therapeutic modalities for high-value, unmet medical needs.

Showing promise in immune-mediated & infectious diseases

Current programs:

- Immuno-oncology
- Gastrointestinal (GI) related disorders
- Antimicrobial resistance (AMR)

Harnessing the human microbiome



10^14

microbes in the human body

Trillions of microorganisms live in & on our bodies

Play an essential role in various daily bodily functions

Microbiome diversity is associated with health & wellbeing

Right field, right time

Industry

Multi $Bn
market opportunity

More than $4Bn
invested in microbiome companies since 2014

Record high investments
In microbiome companies

Areas of focus



Most candidates are still in the discovery & preclinical stages; Increasing number advancing to clinical stage (Ph. II/III)

- Dermatology (8%)
- CNS (7%)
- Other (6%)
- **GI-related disorders (44%)**
- **Cancer & Immune-mediated Diseases (35%)**

Key Players

Big pharma

Johnson & Johnson · Merck · Roche · Ferring Pharmaceuticals · Takeda · Nestlé Health Science

Prominent VCs

OrbiMed · Seventure · Flagship Pioneering

Active companies

Finch Therapeutics · SERES · Vedanta Biosciences · Evelo

Sources:
BCC Research (2017) – Human Microbiome-based Drugs and Diagnostics Market SVB – Emerging Healthcare: Microbiome Investment Trends Aug 2017)

https://www.microbiometimes.com/the-microbiome-biotech-landscape-an-analysis-of-the-pharmaceutical-pipeline/

Right field, right time

The microbiome is flourishing

In Vivo
Informa Pharma Intelligence
17 June, 2021

The Microbiome's Time To Shine

Exclusive Interview With Seventure CEO Isabelle de Cremoux

manufacturing CHEMIST
26 January, 2021

The century of the microbiome: an exciting time for human health

PHARMACEUTICAL TECHNOLOGY
2 July, 2021

Seres and Nestlé enter up to $525m deal for microbiome therapeutic

biopharmadealmakers
30 November, 2020

Early investments powering the ascent of microbiome therapeutics

A clinical promise comes true

BOSTON BUSINESS JOURNAL
Aug 10, 2020

Seres stock jumps 400% on microbiome trial success

businesswire
June 19, 2020

Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent *C. difficile* Infection

nature reviews drug discovery
11 September 2020

First microbiome-based drug clears phase III, in clinical trial turnaround

Positive phase 3 clinical data shows strong validation of microbiome therapeutics.

Limitations of common approaches

	Number of microbial entities	QC	Scalability	Druggability	Patentability	COGS	Targeted multiple functions composition	Potency*	Safety**
Fecal Microbiota Transplantation (FMT)	–	–	–	✓	✓	✓	–	✓	✓
Single-strain method	✓✓	✓✓	✓✓	✓✓	✓	✓✓	–	✓	✓✓
Multi-strain rationally-designed Live biotherapeutic products (LBPs)	✓	✓✓	✓	✓✓	–	✓	–	✓✓	✓

* Higher efficacy due to multiple carefully selected MoAs
** Better safety due to fewer & carefully selected entities

✓✓ Fully addressed ✓ Partial addressed – Not addressed

Finding the optimal combination of microbes is complex

To develop **best-in-class drugs**, one must find, select, and combine **only the most suitable microbes** from the thousands of strains in our bodies.

Each method has its own set of challenges

Biological method:
Healing the sick by comparing them to the healthy

- Slow & exhausting
- 0101 0010 1010 Limited by small data
- Like finding needle in the hay

Computational method:
Using AI to find the key microbes

- Lack of proper tools & datasets
- Poor ability to gain valuable insights

The BIOMICA approach:

Computational, targeted & function-based drug design

1

Modulating a patient's microbiome

2

Computational predictive biology platform

3

Function-based drug design process

1

Modulating a patient's microbiome



2

Computational predictive biology platform

Proven, robust data integration, analysis & prediction

Big data

Databases generated via data integration capabilities



AI

Proprietary computational algorithms utilized to mine data

MicroBoost AI

evogene DECODING BIOLOGY

20 years
of experience

$$$
tens of millions of dollars invested

Validation
through collaborations with industrial leaders & internal results

2

Computational predictive biology platform

Prism
Microbiome target discovery

Holistically determining the best strains for the patient

Patients' microbiome:
Identifies the strains present & the functions they perform

- Strain identifier
- Function finder
- Strain-function allocator

Patients' genetic & clinical data:
Examining the patient's clinical data & genomic data

- Clinical data
- Human genomics
- Consolidator



3

0101
0010
1010

Function based drug design process

An emphasis on microbial function

PRISM allows high resolution analysis to rationally design therapeutics **based on microbial functions***.

This differentiates Biomica from current practices.



* **Functions:**
Genetic elements (e.g. genes, operons, pathway, plasmids) and/or their biosynthetic products (e.g. metabolites, proteins, enzymes)

The optimal combination

Up to 4 bacterial strains are carefully-selected, based on their functions, which may work across several complementary mechanisms.

Minimum
no. of microbial strains

+

Maximum
relevant & complementary functions

=

Optimal therapeutic impact

Biomica's optimal therapeutic outcome

	Number of microbial entities	QC	Scalability	Druggability	Patentability	COGS	Targeted multiple functions composition	Potency*	Safety**
Fecal Microbiota Transplantation (FMT)	–	–	–	✓	✓	✓	–	✓	✓
Single-strain method	✓✓	✓✓	✓✓	✓✓	✓	✓✓	–	✓	✓✓
Multi-strain rationally-designed LBPs	✓	✓✓	✓	✓✓	–	✓	–	✓✓	✓
Biomica's rationally-designed LBPs	✓✓	✓✓	✓✓	✓✓	✓✓	✓✓	✓✓	✓✓	✓✓

* Higher efficacy due to multiple carefully selected MoAs
** Better safety due to fewer & carefully selected entities

✓✓ Fully addressed ✓ Partial addressed – Not addressed

The pipeline

	Program	Indication / Target	Discovery	Preclinical	Phase 1 / POC	Phase 2	Approach
Immuno-oncology	BMC128	Combination Therapy with ICI* for Solid Tumors					
GI-related disorders	BMC333	IBD					
	BMC426	IBS					
Antimicrobial resistance (AMR)	BMC202	C. difficile Infection					
	TBD**	MRSA Infection					

* Immune checkpoint inhibitors

**Biomica in collaboration with Nobel Prize Laureate Prof. Ada Yonath at Weizmann Institute of Science to develop a selective treatment for MRSA infection.

Live biotherapeutics

Small-molecule

1 Cancer immunotherapy

Response to immunotherapy through specific bacterial functions



* Based on Biomica's computational analysis

POC in humans

Modulating gut microbiome improves cancer treatment

Science

NEWS | HEALTH

Fecal transplants could help patients on cancer immunotherapy drugs

Early results hint that benefits seen in mice could extend to people

5 APR 2019 • BY JOCELYN KAISER

www.sciencemag.org/news/2019/04/fecal-transplants-could-help-patients-cancer-immunotherapy-drugs

"…Now, another potential therapy is being tested in clinical studies: fecal transplants. Early results from two groups described at the annual meeting of the American Association for Cancer Research (AACR) here this week suggest some patients who initially did not benefit from immunotherapy drugs saw their tumors stop growing or even shrink after receiving a stool sample from patients for whom the drugs worked...

…One unresolved question is exactly which microbes help ramp up the desired immune activity…"

POC in humans

Modulating gut microbiome improves cancer treatment

Science

Reports

Cite as: E. N. Baruch *et al.*, *Science* 10.1126/science.abb5920 (2020).

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Erez N. Baruch[1,2*†], Ilan Youngster[3,4], Guy Ben-Betzalel[1], Rona Ortenberg[1], Adi Lahat[5], Lior Katz[6], Katerina Adler[7], Daniela Dick-Necula[8], Stephen Raskin[8,9], Naamah Bloch[10], Daniil Rotin[8], Liat Anafi[8], Camila Avivi[8], Jenny Melnichenko[1], Yael Steinberg-Silman[1], Ronac Mamtani[11], Hagit Harati[1], Nethanel Asher[1], Ronnie Shapira-Frommer[1], Tal Brosh-Nissimov[12], Yael Eshet[4,9,13], Shira Ben-Simon[10], Oren Ziv[10], Md Abdul Wadud Khan[14], Moran Amit[15], Nadim J. Ajami[14], Iris Barshack[4,9], Jacob Schachter[1,4], Jennifer A. Wargo[14,16], Omry Koren[10], Gal Markel[1,2,17*‡], Ben Boursi[4,15,18*‡]

www.science.org/doi/10.1126/science.abb5920

Science

Clinical Trials

Davar *et al.*, *Science* **371**, 595–602 (2021)
5 February 2021

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Diwakar Davar[1*], Amiran K. Dzutsev[2*], John A. McCulloch[2], Richard R. Rodrigues[2,3], Joe-Marc Chauvin[1], Robert M. Morrison[1], Richelle N. Deblasio[1], Carmine Menna[1], Quanquan Ding[1], Ornella Pagliano[1], Bochra Zidi[1], Shuowen Zhang[1†], Jonathan H. Badger[2], Marie Vetizou[2], Alicia M. Cole[2], Miriam R. Fernandes[2], Stephanie Prescott[2], Raquel G. F. Costa[2], Ascharya K. Balaji[2],

www.science.org/doi/10.1126/science.abf3363

Combination therapy

Initial focus on solid tumors: Lung cancer (**NSCLC**), renal cell carcinoma (**RCC**), and **melanoma.**
Biomica aims to **improve clinical response** to ICI through immunomodulating combination therapy.





BMC128

Next gen. optimized consortia
A new combination providing the selected microbial functions
& presenting higher likelihood for survival in GI.

BMC128 administered prior to and in combination with anti-PD1

significantly improved anti-tumor activity

ORR (CR+PR):
23.5% vs 34.8%

48% increase in responders

CISION
PR Newswire

8 September, 2020

Biomica Announces Positive Pre-Clinical Results in its Immuno-Oncology Program

USA - English

Biomica's, a subsidiary of Evogene Ltd., live biotherapeutic drug candidate BMC128 administered in combination with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity. Proof-of-concept first-in-man studies expected next year.

The study indicates that pre-treatment with BMC128 **conditions the immune system & primes it for an efficient anti-tumor response**.

* BMC 128 - Comprised of 4 live bacterial strains derived from BMC121 and BMC127

BMC128 demonstrating
efficacy against melanoma

BMC128 significantly enhanced anti-tumor activity, resulting in an increased response of melanoma tumors to anti-PD1

BMC128 demonstrates **increased** Objective Response Rate (**ORR**)

No response in the Anti-PD1 group





CISION
PR Newswire

13 April, 2021

Biomica Announces Positive Pre-Clinical Results, Demonstrating Efficacy of BMC128 in Melanoma

USA · English

Biomica's live biotherapeutic drug candidate, BMC128, significantly increased anti-tumor activity in combination with Immune Checkpoint Inhibitors in Melanoma. First-in-human, proof of concept study expected later this year

These results demonstrate **the potential applicability of BMC128 and its relevance to treating multiple types of solid tumors.**

1 Cancer immunotherapy

Advancing into the clinical phase

- BMC128 consists of **4 live bacterial strains**.
- Results demonstrated a significant **reduction of tumor volume**, and **increased animal survival** compared to anti-PD1 therapy alone.
- **MoA is immune mediated** – Increased tumor inflammation & infiltration of T lymphocytes and NK cells.
- Potential applicability in the treatment **various types of solid tumors**.

CISION
PR Newswire

13 October, 2020

Biomica Announces Initiation of Large-Scale Production of Live Bacterial Product (LBP) Candidate Consortium in its Immuno-Oncology Program

USA - English

The company is advancing to scale-up and GMP batch production, to support anticipated first-in-man proof-of-concept clinical trials next year

Biomica completed large-scale GMP-production of BMC128 to support its **first-in-human** proof of concept clinical study, expected in early **2022**

2 GI-related disorders

IBS & IBD

Irritable bowel syndrome (IBS)*

A common intestinal functional disorder, group of symptoms: Abdominal pain, constipation or diarrhea, bloating, gas & diarrhea.

Inflammatory bowel disease (IBD)

A group of inflammatory conditions of the colon and small intestine (Crohn's disease, ulcerative colitis & pouchitis).

*In collaboration with The University of North Carolina (UNC) at Chapel Hill

Both clearly related to the microbiome

Biomica pushes the barriers posed by existing therapies by addressing the **underlying cause of the disorder, rather than the symptoms.**

https://www.grandviewresearch.com/industry-analysis/irritable-bowel-syndrome-ibs-treatment-market

https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market

IBS (40M)
IBS-D (16M)
IBS-C (14M)
IBS-M (9M)

IBD (3M)
Crohn's disease (2M)
Ulcerative colitis (1M)
Pouchitis (150K)

IBS ($1.5Bn)

IBD ($19.2Bn)

GI-related disorders

Established role for microbiome in IBD etiology

A state of inflammation is associated with reduced richness of microbial taxa and functions

> Gastroenterology. 2017 Feb;152(2):327-339.e4. doi: 10.1053/j.gastro.2016.10.012. Epub 2016 Oct 18.

Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches

R Balfour Sartor [1], Gary D Wu [2]

Affiliations

1 Departments of Medicine, Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Electronic address: rbs@med.unc.edu.
2 Division of Gastroenterology, Perelman School of Medicine, the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: gdwu@mail.med.upenn.edu.

PMID: 27769810 PMCID: PMC5511756 DOI: 10.1053/j.gastro.2016.10.012

BMC333

Optimized drug candidate derived from Biomica's drug candidates BMC321 and BMC322

Aimed to reduce inflammation for treating IBD

> Curr Treat Options Gastroenterol. 2015 Mar;13(1):105-20. doi: 10.1007/s11938-014-0042-7.

Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches

Jonathan J Hansen [1], R Balfour Sartor

Affiliation

1 Department of Medicine, University of North Carolina at Chapel Hill, CB 7032, Chapel Hill, NC, 27599, USA, jjhansen@med.unc.edu.

PMID: 25595930 PMCID: PMC4364996 DOI: 10.1007/s11938-014-0042-7

Drug comprised of 4 bacterial strains, detected through Biomica's proprietary computational functional genomic analysis platform.

Strains selected for their anti-inflammatory functions, complement each other and target both immunocytes and intestinal mucosal cells.

Each strain supports growth and metabolism of other strains, along with favorable gut resident bacteria.

1. pubmed.ncbi.nlm.nih.gov/27769810/
2. pubmed.ncbi.nlm.nih.gov/25595930/

GI-related disorders

BMC321 & BMC322 indicate to
reduce inflammation in a DSS-treated mouse model*

Gut inflammation level During DSS treatment





Inflammation status
Day 7 of DSS treatment



Severe inflammation
(% of total number of mice):
Control - 43% VS. BMC322- 10%

* Preliminary results

BMC333 reduce tissue damage due to inflammation

Study design for testing the anti-inflammatory effect of BMC333 in DSS-induced colitis murine model.

Disease severity along study evaluated by Disease Activity Index (DAI) combined score following DSS administration in BMC333-treated and untreated groups.



Histological evaluation from H&E staining of mice colon sections after DSS administration in BMC333-treated and untreated groups.

3 Antimicrobial resistance (AMR)

Targeting multi-drug resistant bacterium while preserving healthy gut microbiome

C. difficile infection (CDI)

Most common hospital-acquired infections (Over 600,000 a year).

Increasing cause of morbidity and mortality.

Developing a selective anti-bacterial agent designed to inhibit the C. difficile toxin.

Due mostly to hospitalization, the economic cost of CDI (est.) **$5.4Bn**

* Dessi et al. BMC Infectious Diseases (2016) 16:303; Toxins 2016, 8, 134

MRSA infection

A collaboration between Biomica and the Nobel Prize Laureate **Prof. Ada Yonath** at the Weizmann Institute of Science.

In-licensed IP and knowhow generated by Prof. Ada Yonath.

Cause to tens of thousands of annual cases of mortality in the US.

MRSA market in 2025 (est.) **$3.9Bn**

* www.prnewswire.com/news-releases/global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-to-reach-over-us-9-billion-by-2025-upsurge-in-the-consumption-of-antibiotics-across-the-globe-to-fuel-market-growth-observes-transparency-market-research-676949593.html

Upcoming advancements

Predictions for patients' response to ICI

The potential for future drugs

An experienced management team

Elran Haber, PhD, MBA
CEO

Previously served as the CEO of Therapix Biosciences (Nasdaq, TASE: TRPX), leading the company to a successful IPO on Nasdaq and advancing the Company's programs to clinical stage. Spent more than 10 years as Chairman and board member of several privately held, and publicly traded companies. Served in senior executive roles in various life science companies and a private investment firm. Holds a PhD in Pharmaceutical Science and an MBA in Finance & Financial Engineering, both from The Hebrew University of Jerusalem, Israel.

Prof. Yehuda Ringel
CSO

Chief of the Gastroenterology and Hepatology Division of the Meir Medical Center in Israel; Professor of Medicine at Chapel Hill, North Carolina and is affiliated with University of North Carolina Hospitals.
Has more than 30 years of diverse experiences, especially in Gastroenterology and translational research, and is an expert on IBS and functional motility disorders; Recipient of several prestigious awards. MD from Technion Institute of Technology, Israel.

Shiri Meshner, PhD
VP of Research & Development

Previously served as the head & principal investigator of the Dead Sea microbiology lab in the Dead Sea-Arava Science Center.
Spent over 5 years working in the pharma industry both in the US and in Israel (OSI pharmaceuticals and Teva pharmaceuticals). Holds a PhD in systems microbiology from the Department of Physics of Complex Systems at the Weizmann Institute.

Eyal Partuk
VP Finance

10 years experience in corporate finance, public and private companies. Spent the last years as the CFO of a start-up company – involvement in over $200M private fundraising.
Certificated CPA – Hebrew University of Jerusalem.
Ernst & Young alumnus.

Board of directors

Ofer Haviv
Chairman

Mr. Ofer Haviv serves as Evogene's (Nasdaq: EVGN) President and CEO since of late 2004.

Doron Ben Ami
Director

Mr. Doron Ben Ami is a highly experienced executive with a successful track record of more than 20 years of in the Pharma industry.

Kinneret Savitsky, PhD
Director

Dr. Kinneret Livnat-Savitzky is the CEO and board member of FutuRx Ltd (OrbiMed, J&J Innovation and Takeda's accelerator), Kinneret has over 25 years of experience in senior leadership positions in the biopharmaceutical industry.

World-class scientific advisory board & advisors

Prof. Yehuda Ringel

Chief Division of Gastroenterology and Hepatology at Meir Medical Center, Israel. Professor of Medicine at Chapel Hill, North Carolina and is affiliated with University of North Carolina Hospitals.

Prof. Willem M De Vos

Professor and Chair of Microbiology at Wageningen University, the Netherlands and Professor of Human Microbiomics at the University of Helsinki, Finland.

Prof. R. Balfour Sartor

Serves as the Midget Distinguished Professor of Medicine, Microbiology and Immunology and Director of the Multidisciplinary IBD Center at the University of North Carolina, Chapel Hill.

Prof. James Versalovic

Pathologist-In-Chief at Texas Children's Hospital and Director of Texas Children's Microbiome Center, Professor and Vice Chair of Pathology & Immunology at Baylor College of Medicine.

Prof. David Rubin

Section chief of gastroenterology, hepatology, and nutrition at University of Chicago Medicine. Chair-elect of the National Scientific Advisory Committee of the Crohn's and Colitis Foundation.

Dr. Ravid Straussman

Principle investigator of the Tumor microenvironment, tumor microbiome and resistance to anti-cancer therapy lab at the Weizmann Institute of Science, Israel.

POC first-in-human

clinical trial to be initiated early 2022

A phase 1, open-label study to evaluate the safety and tolerability of **BMC128** in combination with anti-PD-1 in patients with **non-small cell lung cancer** (NSCLC), **melanoma** or **renal cell carcinoma** (RCC).

Q1 2022

is the expected start of this study, in a leading medical center in Israel.

12-15 Patients

expected to be enrolled in this phase I trial.

Safety & tolerability

of the BMC128 and anti PD-1 combination will be investigated as primary objective.

Exploratory objectives

are to explore efficacy variables in response to combined treatment with BMC128 and anti PD-1.

Summary

Human microbiome-based therapeutics is a rapidly growing space, and represents a multi $Bn market opportunity.

Biomica develops innovative microbiome-based therapeutics utilizing dedicated computational predictive biology tools.

Biomica's computational tools and unique approach provide a significant differentiation.

First-in-human POC study in cancer slated early 2022.

Focus on high-value clinical programs for the development of therapies for antibiotic resistant bacteria, immuno-oncology and microbiome-related gastrointestinal (GI) disorders.

Experienced management team, board of directors & world-class scientific advisory board.


Thank you!
info@biomica.com